Prevention of postpartum haemorrhage: cost consequences analysis of misoprostol in low-resource settings

Table 6 Univariate sensitivity analyses: Incremental outcomes: comparing oxytocin/misoprostol with oxytocin/no treatment in a cohort of 1000 births

Sensitivity analysis	PPH	Severe PPH	Additional uterotonics	Blood transfusion	Shivering	Fever	Total Cost
Base Case	−22	−2	−6	−4	130	42	-$320
Lower bound of RR^a	−38	−9	−15	−5	109	27	-$792
Higher bound of RR^a	−1	11	6	0	155	64	$645
Lower cost of drugs	−22	−2	−6	−4	130	42	-$377
Higher cost of drugs	−22	−2	−6	−4	130	42	$151
50 % treatment cost	−22	−2	−6	−4	130	42	-$81
200 % treatment cost	−22	−2	−6	−4	130	42	-$798
Health centre $20; hospital $50/night	−22	−2	−6	−4	130	42	-$1 053
Misoprostol vs placebo RR and placebo baseline risks from Hundley [23]
Mean	−31	−6	−21	−15	126	33	-$1 477
Lower bound of RR^b	−45	−7	−27	−16	0	−70	-$1 729
Higher bound of RR^b	−10	−1	−9	−11	397	918	-$824

^aLower and upper 95 % confidence limits for the misoprostol versus placebo relative risks from Tunçalp [14]
^bLower and upper 95 % confidence limits for the misoprostol versus placebo relative risks from Hundley [23]

ISSN: 1471-2393